Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)

摘要: Purpose One third of patients with triple-negative breast cancer (TNBC) achieve pathologic complete response (pCR) standard neoadjuvant chemotherapy (NACT). CALGB 40603 (Alliance), a 2 × factorial, open-label, randomized phase II trial, evaluated the impact adding carboplatin and/or bevacizumab. Patients and Methods (N = 443) stage to III TNBC received paclitaxel 80 mg/m2 once per week (wP) for 12 weeks, followed by doxorubicin plus cyclophosphamide every weeks (ddAC) four cycles, were randomly assigned concurrent (area under curve 6) 3 cycles bevacizumab 10 mg/kg nine cycles. Effects these agents on pCR (ypT0/is), breast/axilla (ypT0/isN0), treatment delivery, toxicities analyzed. Results either or less likely wP ddAC without skipped doses, dose modification, early discontinuation resulting from ...